ABUS vs PFE · P/E 5.4, rev $6.2M vs P/E 20, rev $62.58B
Arbutus Biopharma Corp (ABUS) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the ABUS and PFE stock pages for the full models.
Not investment advice.